Skip to contentA
Amneal Pharmaceuticals, Inc.
A
AMRXAmneal Pharmaceuticals, Inc. Q2 2023 · 10-Q
Revenue$599.05M$599.05M+7.1% vs Q2 2022 Net Income$11.92M$11.92MN/M vs Q2 2022 EPS Diluted$0.08$0.08N/M vs Q2 2022 Gross Profit$220,021,000+9.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amneal Pharmaceuticals, Inc. · CIK 1723128 · Engraved from SEC EDGAR
Operating Cash Flowderived-$11,345,000N/M Free Cash Flowderived-$23,348,000N/M Margins · derivedGross margin36.7%+0.9 pt vs Q2 2022
Operating margin13.4%+48.9 pt vs Q2 2022
Net margin2.0%+45.3 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 8, 2023 · 39 d after period end